Brought to you by 
Auspex Pharmaceuticals closes $19.5mm Series E round
30 Mar 2015
Executive Summary
Not even a month after filing for its IPO, orphan disease therapeutics-focused Auspex Pharmaceuticals Inc. brought in $19.5mm through a Series E venture round led by Deerfield Management Co. Existing investors Thomas, McNerney and Partners, CMEA Capital, Panorama Capital, BioMed Ventures, and Costa Verde Capital also participated. The company issued 11.3mm shares of Series E convertible preferred shares priced at $1.72. Auspex also concurrently got a $15mm, four-year term loan from Oxford Finance and appointed to its board Gerald Proehl, former president and CEO of gastrointestinal and metabolic disease medicines company Santarus. Auspex uses its deuterium substitution chemistry platform to enhance existing therapeutics for various hyperkinetic movement disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Auspex Pharmaceuticals closes $19.5mm Series E round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice